BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35612815)

  • 1. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia.
    Loke J; Labopin M; Craddock C; Cornelissen JJ; Labussière-Wallet H; Wagner-Drouet EM; Van Gorkom G; Schaap NPM; Kröger NM; Veelken JH; Rovira M; Menard AL; Bug G; Bazarbachi A; Giebel S; Brissot E; Nagler A; Esteve J; Mohty M
    Cancer; 2022 Aug; 128(15):2922-2931. PubMed ID: 35612815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.
    Xu N; Lai YY; Chen WM; Jiang H; Wang Y; Wang X; Zhao XS; Huang XJ; Jiang Q; Qin YZ
    Int J Lab Hematol; 2022 Oct; 44(5):892-899. PubMed ID: 35505580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.
    Vasudevan Nampoothiri R; Chen S; Pasic I; Al-Shaibani Z; Lam W; Michelis FV; Kim DDH; Viswabandya A; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Law AD
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):134-140. PubMed ID: 33049225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Survival efficacy of MDS/AML patients with TP53 abnormal received allogeneic hematopoietic stem cell transplantation].
    Feng D; Wang MY; Liu J; Zhang HX; Chen X; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):222-229. PubMed ID: 37356984
    [No Abstract]   [Full Text] [Related]  

  • 6. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
    Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
    Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
    Poiré X; Labopin M; Maertens J; Yakoub-Agha I; Blaise D; Ifrah N; Socié G; Gedde-Dhal T; Schaap N; Cornelissen JJ; Vigouroux S; Sanz J; Michaux L; Esteve J; Mohty M; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):20. PubMed ID: 28100265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.
    Nagler A; Labopin M; Craddock C; Socié G; Yakoub-Agha I; Gedde-Dahl T; Niittyvuopio R; Byrne JL; Cornelissen JJ; Labussière-Wallet H; Arcese W; Milpied N; Esteve J; Canaani J; Mohty M
    Am J Hematol; 2022 Mar; 97(3):274-282. PubMed ID: 34978724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions.
    Bi X; French Z; Palmisiano N; Wen KY; Wilde L
    Ann Hematol; 2022 Jun; 101(6):1251-1259. PubMed ID: 35288759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
    Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia.
    Yoshida S; Onozawa M; Miyashita N; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Hirabayashi S; Mori A; Hidaka D; Minauchi K; Shigematsu A; Hashiguchi J; Igarashi T; Kakinoki Y; Tsutsumi Y; Ibata M; Kobayashi H; Haseyama Y; Fujimoto K; Ishihara T; Sakai H; Ota S; Kondo T; Teshima T
    Int J Hematol; 2023 Apr; 117(4):544-552. PubMed ID: 36572814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Cytogenetic Evolution on the Outcome of Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Nonremission: A Single-Institute Analysis of 212 Recipients.
    Yuasa M; Yamamoto H; Mitsuki T; Kageyama K; Kaji D; Taya Y; Nishida A; Ishiwata K; Takagi S; Yamamoto G; Asano-Mori Y; Wake A; Koike Y; Makino S; Uchida N; Taniguchi S
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2262-2270. PubMed ID: 32871257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
    Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
    Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
    Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution.
    Nahi H; Remberger M; Machaczka M; Ungerstedt J; Mattson J; Ringden O; Le-Blanc K; Ljungman P; Hägglund H
    Med Oncol; 2012 Dec; 29(4):2348-58. PubMed ID: 22234457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT.
    Najima Y; Sadato D; Harada Y; Oboki K; Hirama C; Toya T; Doki N; Haraguchi K; Yoshifuji K; Akiyama M; Inamoto K; Igarashi A; Kobayashi T; Kakihana K; Okuyama Y; Sakamaki H; Harada H; Ohashi K
    Bone Marrow Transplant; 2021 Feb; 56(2):334-346. PubMed ID: 32760007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.
    Middeke JM; Herold S; Rücker-Braun E; Berdel WE; Stelljes M; Kaufmann M; Schäfer-Eckart K; Baldus CD; Stuhlmann R; Ho AD; Einsele H; Rösler W; Serve H; Hänel M; Sohlbach K; Klesse C; Mohr B; Heidenreich F; Stölzel F; Röllig C; Platzbecker U; Ehninger G; Bornhäuser M; Thiede C; Schetelig J;
    Br J Haematol; 2016 Mar; 172(6):914-22. PubMed ID: 26771088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.